Eli Lilly’s existing non-exclusive evaluation agreement with Peptron, signed in October 2024 and extended through October 7, 2026, remains confined to joint R&D on SmartDepot microsphere formulations for peptide candidates, including GLP-1 agents, without granting commercial rights. Recent in-vivo studies and scope expansions into CNS indications show continued technical validation, yet no binding technology transfer or licensing announcements have emerged, while Lilly pursues competing sustained-release platforms such as Camurus’ FluidCrystal. With the deadline days away and the current pact explicitly terminable on short notice, traders see negligible likelihood of a qualifying commercial deal materializing in time.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於13% 機率
$11,486 交易量
$11,486 交易量
2026-10-07
13% 機率
$11,486 交易量
$11,486 交易量
2026-10-07
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing non-exclusive evaluation agreement with Peptron, signed in October 2024 and extended through October 7, 2026, remains confined to joint R&D on SmartDepot microsphere formulations for peptide candidates, including GLP-1 agents, without granting commercial rights. Recent in-vivo studies and scope expansions into CNS indications show continued technical validation, yet no binding technology transfer or licensing announcements have emerged, while Lilly pursues competing sustained-release platforms such as Camurus’ FluidCrystal. With the deadline days away and the current pact explicitly terminable on short notice, traders see negligible likelihood of a qualifying commercial deal materializing in time.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
市場開放時間： May 5, 2026, 8:02 PM ET
交易量
$11,486結束日期
2026-10-07市場開放時間
May 5, 2026, 8:02 PM ETThis market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing non-exclusive evaluation agreement with Peptron, signed in October 2024 and extended through October 7, 2026, remains confined to joint R&D on SmartDepot microsphere formulations for peptide candidates, including GLP-1 agents, without granting commercial rights. Recent in-vivo studies and scope expansions into CNS indications show continued technical validation, yet no binding technology transfer or licensing announcements have emerged, while Lilly pursues competing sustained-release platforms such as Camurus’ FluidCrystal. With the deadline days away and the current pact explicitly terminable on short notice, traders see negligible likelihood of a qualifying commercial deal materializing in time.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
交易量
$11,486結束日期
2026-10-07市場開放時間
May 5, 2026, 8:02 PM ETEli Lilly’s existing non-exclusive evaluation agreement with Peptron, signed in October 2024 and extended through October 7, 2026, remains confined to joint R&D on SmartDepot microsphere formulations for peptide candidates, including GLP-1 agents, without granting commercial rights. Recent in-vivo studies and scope expansions into CNS indications show continued technical validation, yet no binding technology transfer or licensing announcements have emerged, while Lilly pursues competing sustained-release platforms such as Camurus’ FluidCrystal. With the deadline days away and the current pact explicitly terminable on short notice, traders see negligible likelihood of a qualifying commercial deal materializing in time.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions